Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in STEC-HUS
NCT01410916Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2011
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS), sponsored by Alexion Pharmaceuticals. Started Jul 2011; status: completed.
02
Drugs
eculizumab
03
Conditions
Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS)
Beyond the preview
Go deeper on NCT01410916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01410916.